Javascript must be enabled to continue!
Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago
View through CrossRef
Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.3±6.4 years, 19.8±13% and 6.8±5% respectively. Mean aortic valve gradient decreased from 49.8±15 mm Hg to 8.6±3.8 mmHg after TAVI, to 11.1±9 mm Hg at 5 years, and 25.7±12 mmHg at 7 years (p for post-TAVI trend 0.03). Mean aortic valve area increased from 0.63±0.16 cm2 to 1.57±0.3cm2 after TAVI to 1.48±0.2 at 5 years and 0.87±0.3 cm2 at 7 years (p for post-TAVI trend 0.01). Mean left ventricular ejection fraction increased from 61.1±15% to 65.5±11% after TAVI, to 58.2±17% at 5 years and 57.2±8% at 7 years (p for post-TAVI trend 0.001).
The total mortality after a mean of 53±34 months was 73% and 34.4% was cardiovascular mortality. Survival rates at 1 to 10 years were at 86%, 75.4%, 64.9%, 59.6%, 52.6%, 33.1%, 24.9%, 20.7%, 10.4% and 10.4% respectively. Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation). Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.89 to 6.28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.874; 95% CI: 1.028 to 3.418), p=0.040, Charlson index [HR=1.212 (95% CI: 1.094–1.341), p<0.001], and age [HR=1.03; (95% CI: 1.001–1.062), p=0.049].
Conclusions
In our center, the transcatheter aortic valve implantation in patients at high surgical risk, presented favourable clinical outcomes and hemodynamic performance after ten years of follow-up.
Funding Acknowledgement
Type of funding sources: None.
Title: Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago
Description:
Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown.
The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.
3±6.
4 years, 19.
8±13% and 6.
8±5% respectively.
Mean aortic valve gradient decreased from 49.
8±15 mm Hg to 8.
6±3.
8 mmHg after TAVI, to 11.
1±9 mm Hg at 5 years, and 25.
7±12 mmHg at 7 years (p for post-TAVI trend 0.
03).
Mean aortic valve area increased from 0.
63±0.
16 cm2 to 1.
57±0.
3cm2 after TAVI to 1.
48±0.
2 at 5 years and 0.
87±0.
3 cm2 at 7 years (p for post-TAVI trend 0.
01).
Mean left ventricular ejection fraction increased from 61.
1±15% to 65.
5±11% after TAVI, to 58.
2±17% at 5 years and 57.
2±8% at 7 years (p for post-TAVI trend 0.
001).
The total mortality after a mean of 53±34 months was 73% and 34.
4% was cardiovascular mortality.
Survival rates at 1 to 10 years were at 86%, 75.
4%, 64.
9%, 59.
6%, 52.
6%, 33.
1%, 24.
9%, 20.
7%, 10.
4% and 10.
4% respectively.
Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation).
Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.
89 to 6.
28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.
874; 95% CI: 1.
028 to 3.
418), p=0.
040, Charlson index [HR=1.
212 (95% CI: 1.
094–1.
341), p<0.
001], and age [HR=1.
03; (95% CI: 1.
001–1.
062), p=0.
049].
Conclusions
In our center, the transcatheter aortic valve implantation in patients at high surgical risk, presented favourable clinical outcomes and hemodynamic performance after ten years of follow-up.
Funding Acknowledgement
Type of funding sources: None.
Related Results
Transcatheter aortic valve implantation in degenerated trans-catheter and surgical bioprosthetic aortic valve
Transcatheter aortic valve implantation in degenerated trans-catheter and surgical bioprosthetic aortic valve
Abstract
Background
The moving forward indication of transcatheter aortic valve implantation (TAVI) to younger aortic valve sten...
AORTIC ROOT ANEURYSM OR ECTASIA TREATED WITH AORTIC ROOT WRAPPED PROCEDURE
AORTIC ROOT ANEURYSM OR ECTASIA TREATED WITH AORTIC ROOT WRAPPED PROCEDURE
Objectives
To develop a relatively simple and effective and less risk operation, aortic root wrapped procedure, to treat with aortic root aneurysm or ectasia.
...
Valve-Sparing Aortic Root Replacement by Congenital Heart Surgeons: A Single Center Experience.
Valve-Sparing Aortic Root Replacement by Congenital Heart Surgeons: A Single Center Experience.
Background Aortic root dilatation and aortic insufficiency can
occur in patients with prior conotruncal defect surgery, the Ross
procedure, and connective tissue disease (CTD). Val...
Techniques of Aortic Valve Repair
Techniques of Aortic Valve Repair
Similar to mitral repair, newer methods of aortic valve reconstruction are achieving excellent outcomes with an 85% to 90% freedom from valve-related complications at 10 years. The...
Incidence, predictors and outcomes of Valve-in-valve (ViV) Transcatheter aortic valve replacement (TAVR): a systematic review and meta-analysis
Incidence, predictors and outcomes of Valve-in-valve (ViV) Transcatheter aortic valve replacement (TAVR): a systematic review and meta-analysis
Abstract
Background
Surgical aortic valve replacement has been the treatment of choice for patients with aortic valve disease be...
Ten year follow‐up of high‐risk patients treated during the early experience with transcatheter aortic valve replacement
Ten year follow‐up of high‐risk patients treated during the early experience with transcatheter aortic valve replacement
AbstractBackgroundThe long‐term clinical performance of transcatheter heart valves (THV) is unknown.AimsThis study assessed the clinical outcomes, rate of structural valve deterior...
e0541 Percutaneous valved stent implantation above the coronary ostia: a new transitional treatment for acute aortic valve rupture
e0541 Percutaneous valved stent implantation above the coronary ostia: a new transitional treatment for acute aortic valve rupture
Objective
To investigate the feasibility of percutaneous valved stent implantation above the coronary ostia as a transitional treatment for acute aortic valve rup...
Infective endocarditis of quadricuspid aortic valve
Infective endocarditis of quadricuspid aortic valve
Abstract
Background
Infective endocarditis of the aortic valve is a relatively common disease presentation, with surgical intervention a mainstay of...

